TIGERMED (03347) Income Statement & Earnings

40.160
+0.580+1.47%

Market Closed Apr 30 16:01 CST

34.58BMarket Cap39.57P/E (TTM)

TIGERMED (03347) Income Statement

All

YOY

Hide blank lines

(Q1)Mar 31, 2026

(FY)Dec 31, 2025

(Q9)Sep 30, 2025

(Q6)Jun 30, 2025

(Q1)Mar 31, 2025

(FY)Dec 31, 2024

(Q9)Sep 30, 2024

(Q6)Jun 30, 2024

(Q1)Mar 31, 2024

(FY)Dec 31, 2023

Turnover

15.17%1.8B

3.48%6.83B

-0.82%5.03B

-3.21%3.25B

-5.79%1.56B

-10.58%6.6B

-10.32%5.07B

-9.50%3.36B

-8.00%1.66B

4.21%7.38B

Operating income

15.17%1.8B

3.48%6.83B

-0.82%5.03B

-3.21%3.25B

-5.79%1.56B

-10.58%6.6B

-10.32%5.07B

-9.50%3.36B

-8.00%1.66B

4.21%7.38B

Operating expenses

-20.76%-1.32B

-13.72%-4.96B

-14.95%-3.56B

-12.21%-2.27B

-6.04%-1.09B

3.85%-4.36B

8.12%-3.1B

9.17%-2.03B

5.23%-1.03B

-5.48%-4.54B

Gross profit

2.16%479.89M

-16.45%1.87B

-25.61%1.47B

-26.64%977.98M

-25.21%469.76M

-21.29%2.24B

-13.57%1.97B

-10.00%1.33B

-12.21%628.12M

2.26%2.85B

Selling expenses

-15.39%-56.19M

-13.03%-234.66M

-21.05%-175.45M

-6.44%-107.91M

-4.83%-48.7M

-10.83%-207.61M

-9.22%-144.94M

-13.91%-101.38M

-3.43%-46.45M

-24.97%-187.31M

Administrative expenses

3.91%-173.43M

1.48%-725.91M

4.94%-530.84M

5.66%-355.29M

-1.93%-180.49M

-13.33%-736.84M

-5.85%-558.43M

-8.70%-376.62M

-3.60%-177.07M

-1.07%-650.2M

Research and development expenses

-6.06%-62.66M

-8.08%-257.64M

-11.12%-191.24M

-1.85%-127M

7.56%-59.08M

8.86%-238.39M

11.90%-172.1M

2.65%-124.69M

0.95%-63.91M

-11.48%-261.56M

Profit from asset sales

-180.31%-463.47K

2.45%3.65M

95.26%5.22M

-58.00%625.76K

-49.92%577.12K

1,994.43%3.56M

5,815.94%2.67M

25,346.07%1.49M

32,651.46%1.15M

---188.09K

Revaluation surplus

971.02%195.04M

108.42%42.26M

1,039.18%323.19M

8.90%-89.64M

-275.58%-22.39M

-242.21%-501.69M

-104.84%-34.41M

-118.58%-98.4M

-92.77%12.75M

--352.77M

-Changes in the fair value of other assets

971.02%195.04M

108.42%42.26M

1,039.18%323.19M

8.90%-89.64M

-275.58%-22.39M

-242.21%-501.69M

-104.84%-34.41M

-118.58%-98.4M

-92.77%12.75M

--352.77M

Impairment and provision

79.07%-3.06M

-8.88%-37.04M

41.36%-32.31M

18.77%-29.31M

20.54%-14.62M

50.04%-34.02M

-21.51%-55.1M

-21.18%-36.08M

11.22%-18.4M

-177.10%-68.1M

-Other impairment is provision

79.07%-3.06M

-8.88%-37.04M

41.36%-32.31M

18.77%-29.31M

20.54%-14.62M

50.04%-34.02M

-21.51%-55.1M

-21.18%-36.08M

11.22%-18.4M

-177.10%-68.1M

Special items of operating profit

50.26%57.43M

136.08%480.4M

256.80%466.56M

188.79%254.41M

224.47%38.22M

-45.38%203.49M

-5.47%130.76M

-18.28%88.09M

-61.93%11.78M

-58.85%372.54M

Operating profit

142.83%428M

57.91%1.11B

16.91%1.31B

-24.36%507.54M

-48.20%176.25M

-70.47%702.49M

-49.39%1.12B

-55.58%670.96M

-44.66%340.28M

-9.84%2.38B

Financing income

----

-83.23%15.13M

----

-88.20%8.42M

----

-60.75%90.22M

----

-41.75%71.38M

----

--229.85M

Financing cost

----

35.88%-90.56M

----

19.32%-54.4M

----

-17.80%-141.24M

----

-27.68%-67.43M

----

-44.14%-119.9M

Special items of earning before tax

112.03%105.78K

-14,700.75%-6.2M

-401.04%-6.23M

-151.87%-1.57M

-623.31%-879.04K

-97.33%42.5K

-24.63%2.07M

452.48%3.02M

2.21%167.98K

--1.59M

Earning before tax

182.64%405.94M

50.98%1B

12.48%1.22B

-35.85%442.69M

-60.36%143.63M

-73.30%664.46M

-53.03%1.09B

-56.85%690.09M

-42.58%362.36M

-4.10%2.49B

After-tax profit from continuing operations

200.13%330.08M

79.77%805.06M

20.88%1.09B

-34.93%362.83M

-64.81%109.98M

-79.17%447.83M

-55.46%903.14M

-60.40%557.58M

-45.00%312.57M

-5.76%2.15B

Earning after tax

200.13%330.08M

79.77%805.06M

20.88%1.09B

-34.93%362.83M

-64.81%109.98M

-79.17%447.83M

-55.46%903.14M

-60.40%557.58M

-45.00%312.57M

-5.76%2.15B

Minority profit

606.49%281.04M

-294.05%-82.83M

-20.58%71.25M

-131.68%-20.51M

-171.60%-55.49M

-65.87%42.69M

-39.49%89.71M

227.70%64.73M

59,975.46%77.5M

-52.83%125.08M

Profit attributable to shareholders

-70.36%49.04M

119.15%887.89M

25.45%1.02B

-22.22%383.34M

-29.61%165.47M

-79.99%405.14M

-56.72%813.43M

-64.50%492.85M

-58.65%235.07M

0.43%2.02B

Basic earnings per share

-68.42%0.06

121.28%1.04

26.60%1.19

-21.05%0.45

-29.63%0.19

-79.91%0.47

-56.68%0.94

-64.60%0.57

-59.09%0.27

0.43%2.34

Diluted earnings per share

-68.42%0.06

121.28%1.04

26.60%1.19

-21.05%0.45

-29.63%0.19

-79.91%0.47

-56.68%0.94

-64.60%0.57

-59.09%0.27

0.43%2.34

Currency Unit

CNY

Accounting Standards

CAS (2007)

Audit Opinions

Unqualified Opinion

Auditor

Lixin Certified Public Accountants (Special General Partnership), Lixin Dehao Certified Public Accountants Limited (Hong Kong)

	(Q1)Mar 31, 2026	(FY)Dec 31, 2025	(Q9)Sep 30, 2025	(Q6)Jun 30, 2025	(Q1)Mar 31, 2025	(FY)Dec 31, 2024	(Q9)Sep 30, 2024	(Q6)Jun 30, 2024	(Q1)Mar 31, 2024	(FY)Dec 31, 2023
Turnover	15.17%1.8B	3.48%6.83B	-0.82%5.03B	-3.21%3.25B	-5.79%1.56B	-10.58%6.6B	-10.32%5.07B	-9.50%3.36B	-8.00%1.66B	4.21%7.38B
Operating income	15.17%1.8B	3.48%6.83B	-0.82%5.03B	-3.21%3.25B	-5.79%1.56B	-10.58%6.6B	-10.32%5.07B	-9.50%3.36B	-8.00%1.66B	4.21%7.38B
Operating expenses	-20.76%-1.32B	-13.72%-4.96B	-14.95%-3.56B	-12.21%-2.27B	-6.04%-1.09B	3.85%-4.36B	8.12%-3.1B	9.17%-2.03B	5.23%-1.03B	-5.48%-4.54B
Gross profit	2.16%479.89M	-16.45%1.87B	-25.61%1.47B	-26.64%977.98M	-25.21%469.76M	-21.29%2.24B	-13.57%1.97B	-10.00%1.33B	-12.21%628.12M	2.26%2.85B
Selling expenses	-15.39%-56.19M	-13.03%-234.66M	-21.05%-175.45M	-6.44%-107.91M	-4.83%-48.7M	-10.83%-207.61M	-9.22%-144.94M	-13.91%-101.38M	-3.43%-46.45M	-24.97%-187.31M
Administrative expenses	3.91%-173.43M	1.48%-725.91M	4.94%-530.84M	5.66%-355.29M	-1.93%-180.49M	-13.33%-736.84M	-5.85%-558.43M	-8.70%-376.62M	-3.60%-177.07M	-1.07%-650.2M
Research and development expenses	-6.06%-62.66M	-8.08%-257.64M	-11.12%-191.24M	-1.85%-127M	7.56%-59.08M	8.86%-238.39M	11.90%-172.1M	2.65%-124.69M	0.95%-63.91M	-11.48%-261.56M
Profit from asset sales	-180.31%-463.47K	2.45%3.65M	95.26%5.22M	-58.00%625.76K	-49.92%577.12K	1,994.43%3.56M	5,815.94%2.67M	25,346.07%1.49M	32,651.46%1.15M	---188.09K
Revaluation surplus	971.02%195.04M	108.42%42.26M	1,039.18%323.19M	8.90%-89.64M	-275.58%-22.39M	-242.21%-501.69M	-104.84%-34.41M	-118.58%-98.4M	-92.77%12.75M	--352.77M
-Changes in the fair value of other assets	971.02%195.04M	108.42%42.26M	1,039.18%323.19M	8.90%-89.64M	-275.58%-22.39M	-242.21%-501.69M	-104.84%-34.41M	-118.58%-98.4M	-92.77%12.75M	--352.77M
Impairment and provision	79.07%-3.06M	-8.88%-37.04M	41.36%-32.31M	18.77%-29.31M	20.54%-14.62M	50.04%-34.02M	-21.51%-55.1M	-21.18%-36.08M	11.22%-18.4M	-177.10%-68.1M
-Other impairment is provision	79.07%-3.06M	-8.88%-37.04M	41.36%-32.31M	18.77%-29.31M	20.54%-14.62M	50.04%-34.02M	-21.51%-55.1M	-21.18%-36.08M	11.22%-18.4M	-177.10%-68.1M
Special items of operating profit	50.26%57.43M	136.08%480.4M	256.80%466.56M	188.79%254.41M	224.47%38.22M	-45.38%203.49M	-5.47%130.76M	-18.28%88.09M	-61.93%11.78M	-58.85%372.54M
Operating profit	142.83%428M	57.91%1.11B	16.91%1.31B	-24.36%507.54M	-48.20%176.25M	-70.47%702.49M	-49.39%1.12B	-55.58%670.96M	-44.66%340.28M	-9.84%2.38B
Financing income	----	-83.23%15.13M	----	-88.20%8.42M	----	-60.75%90.22M	----	-41.75%71.38M	----	--229.85M
Financing cost	----	35.88%-90.56M	----	19.32%-54.4M	----	-17.80%-141.24M	----	-27.68%-67.43M	----	-44.14%-119.9M
Special items of earning before tax	112.03%105.78K	-14,700.75%-6.2M	-401.04%-6.23M	-151.87%-1.57M	-623.31%-879.04K	-97.33%42.5K	-24.63%2.07M	452.48%3.02M	2.21%167.98K	--1.59M
Earning before tax	182.64%405.94M	50.98%1B	12.48%1.22B	-35.85%442.69M	-60.36%143.63M	-73.30%664.46M	-53.03%1.09B	-56.85%690.09M	-42.58%362.36M	-4.10%2.49B
After-tax profit from continuing operations	200.13%330.08M	79.77%805.06M	20.88%1.09B	-34.93%362.83M	-64.81%109.98M	-79.17%447.83M	-55.46%903.14M	-60.40%557.58M	-45.00%312.57M	-5.76%2.15B
Earning after tax	200.13%330.08M	79.77%805.06M	20.88%1.09B	-34.93%362.83M	-64.81%109.98M	-79.17%447.83M	-55.46%903.14M	-60.40%557.58M	-45.00%312.57M	-5.76%2.15B
Minority profit	606.49%281.04M	-294.05%-82.83M	-20.58%71.25M	-131.68%-20.51M	-171.60%-55.49M	-65.87%42.69M	-39.49%89.71M	227.70%64.73M	59,975.46%77.5M	-52.83%125.08M
Profit attributable to shareholders	-70.36%49.04M	119.15%887.89M	25.45%1.02B	-22.22%383.34M	-29.61%165.47M	-79.99%405.14M	-56.72%813.43M	-64.50%492.85M	-58.65%235.07M	0.43%2.02B
Basic earnings per share	-68.42%0.06	121.28%1.04	26.60%1.19	-21.05%0.45	-29.63%0.19	-79.91%0.47	-56.68%0.94	-64.60%0.57	-59.09%0.27	0.43%2.34
Diluted earnings per share	-68.42%0.06	121.28%1.04	26.60%1.19	-21.05%0.45	-29.63%0.19	-79.91%0.47	-56.68%0.94	-64.60%0.57	-59.09%0.27	0.43%2.34
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)
Audit Opinions	--	--	--	--	--	Unqualified Opinion	--	--	--	Unqualified Opinion
Auditor	--	--	--	--	--	Lixin Certified Public Accountants (Special General Partnership), Lixin Dehao Certified Public Accountants Limited (Hong Kong)	--	--	--	Lixin Certified Public Accountants (Special General Partnership), Lixin Dehao Certified Public Accountants Limited (Hong Kong)

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"